Podcasts about Breast cancer

If doctors can catch breast cancer early enough, the chances of survival are about 90%. In order to catch it early enough, women over the age of 40 usually get annual mammograms, paid for by their health insurance. Roughly half of those women have dense breast tissue that requires additional screenings, however, which aren't always covered by insurance. Also: a record-high stock market and the state of the economy surrounding the Strait of Hormuz.

If doctors can catch breast cancer early enough, the chances of survival are about 90%. In order to catch it early enough, women over the age of 40 usually get annual mammograms, paid for by their health insurance. Roughly half of those women have dense breast tissue that requires additional screenings, however, which aren't always covered by insurance. Also: a record-high stock market and the state of the economy surrounding the Strait of Hormuz.

Welcome to the podcast with Dr. Brendan McCarthy!   In this episode, he dives deep into the powerful potential, and the necessary precautions, of testosterone replacement therapy (TRT) in women. He shares why this once-taboo treatment is gaining traction, how it may reduce the risk of breast cancer by up to 50%, and why lab testing and clinical nuance are absolutely non-negotiable. Dr. McCarthy also addresses medical betrayal, the rise of influencer-driven misinformation, and what it means to receive care rooted in science, safety, and trust. If you've ever been confused, dismissed, or overwhelmed by hormone therapy conversations, this one's for you.  

Dr Bill Nelson talks to Dr Andrew Ewald, a cell biologist, about his research into how cancer cells migrate throughout the body and the importance of federal funding to continue building on decades of successful research efforts.

218: In this episode, I'm covering one of the most requested and controversial topics in women's health—whether breast cancer survivors can safely use hormone replacement therapy (HRT). To help answer this complex question, I'm joined by Dr. Corinne Menn, a board-certified OB-GYN, Menopause Society certified practitioner, and Fellow of the American College of Obstetrics and Gynecology. Dr. Menn brings a powerful blend of clinical expertise and lived experience. She's a 23-year breast cancer survivor, BRCA gene carrier, and went through premature menopause herself. We cover what the research really says about HRT after breast cancer, risks versus benefits, the reality of estrogen deprivation, and why “it depends” is the only honest answer. Topics Discussed: → Can breast cancer survivors safely use HRT? → Is hormone therapy after breast cancer risky? → What are the benefits of estrogen for cancer survivors? → Does HRT increase breast cancer recurrence? → Are there safe hormone options for BRCA carriers? Sponsored By: → Timeline | Head to timeline.com/DRTYNA and get 20% off with code DRTYNA  → Nutrisense | Head over to nutrisense.io/drtyna to get 30% off your Nutrisense plan. Code TYNA at checkout → LVLUP | Head over to LVLUPHealth.com and use code DRTYNA at checkout to get 20% off your order sitewide.  → Manukora | Head to manukora.com/DRTYNA to save up to 31% & $25 worth of free gifts in Starter Kit, which comes with an MGO 850+ Manuka Honey jar. → BIOptimizers | Go to bioptimizers.com/tyna and use promo code TYNA10 to order Masszymes now and get 10% off any order → Dr Tyna's Brain spark | Go to store.drtyna.com/products/brainspark and use code BRAINSPARK10 for 10%  On This Episode We Cover:  → 00:00:00 - Introduction  → 00:04:51 - Dr. Menn's cancer story → 00:07:09 - Estrogen loss effects → 00:11:45 - Surgical menopause → 00:15:05 - Estrogen and cancer risk → 00:25:32 - Pregnancy after cancer → 00:31:40 - Estrogen in midlife → 00:34:45 - HRT after breast cancer → 00:37:56 - Recurrence risk → 00:44:06 - Dangers of low estrogen → 00:50:34 - New HRT options → 00:58:05 - Sexual health & dryness → 01:04:02 - You don't need to suffer → 01:08:16 - Estrogen and surgery → 01:13:04 - Estrogen for tissue health Show Links: → Estrogen Matters (book) Further Listening:  → EP. 199 | Hot Flashes Are a Warning Sign: The Truth About Metabolic Dysfunction | Quick + Dirty → Hormones Playlist Check Out Dr. Menn: → Instagram  → Website  → More Dr. Menn Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Jesse J reveals that she has been battling breast cancer and is recovering from surgery. Cardi B is releasing a new album on September 19th. And, Dolly Parton announces a Las Vegas residency!See omnystudio.com/listener for privacy information.

What happens when your gender journey and a breast cancer diagnosis collide? In this special Pride Month episode of Real Pink, our guests are Ash Davidson, a trans masculine activist who went in for gender-affirming top surgery and left with a breast cancer diagnosis and Scout, executive director of the National LGBT Cancer Network. They'll help us dive into the challenges and care gaps trans and nonbinary people face when navigating a breast cancer diagnosis. And together, we'll explore what true gender-affirming care looks like, how to self-advocate in a medical system not built for everyone, and why inclusive, trauma-informed support isn't just kind — it's lifesaving.

Grading & Staging Breast Cancer – Know the Hidden DangersIn this episode, Dr. Barbara 'Menopause' Taylor breaks down the critical differences between grading and staging breast cancer—and exposes the hidden dangers that often leave patients confused or misinformed. Learn how cancer cell "grades" reflect aggressiveness, how "stages" indicate spread, and why stage 0 (carcinoma in situ) can be misleading. With clarity and compassion, Dr. Taylor empowers you to understand your diagnosis and advocate for informed treatment decisions.Visual learner? Find the corresponding Menopause Taylor YouTube video here. Click here for more about one-on-one consultations and Dr. Taylor's menopause resources. Looking for a roadmap to successful menopause management? Dr. Taylor's new ebook, How to Win at Menopause: A Guide to Raising - and Winning- Your Game Your Way, will bring confidence and clarity to your menopause journey. Avoid common pitfalls and learn to navigate a healthcare system that focuses more on disease than prevention, where many professionals lack the relevant education and/or the motivation to help you.

Welcome to the 100th episode of Keeping Abreast! In this powerful episode of Dr. Jenn answers questions from her listeners and dives deep into the most commonly asked questions over the years. She discusses the evolution of breast cancer screening, emphasizing the importance of self-examination and the innovative QT scan technology. I address the challenges faced by breast cancer survivors, the role of hormone replacement therapy and the real reasons women feel worse after treatment and what to do about it.  Dr Jenn discusses the significance and impactful difference of personalized health care. I share my views on taking a holistic view of health, encouraging women to take charge of their well-being and to address emotional trauma as part of recovery. This episode highlights the need for a shift in how breast cancer care is approached, focusing on prevention and self-care. She gives women what she once wishes she had, real answers, a new approach and hope.  In This Episode You Will Learn:- Self-breast examination is crucial for early detection.- The ARIA test provides real-time risk assessment for breast cancer.- QT scan technology offers a safer alternative to traditional imaging.- Post-treatment, many women experience significant health challenges.- Hormone replacement therapy can be safe after breast cancer with proper monitoring.- Emotional trauma plays a significant role in recovery from breast cancer.- Personalized health approaches are essential for effective treatment.- Education about breast cancer and its treatment is vital for patients.- Women deserve to thrive after a breast cancer diagnosis, not just survive.- Health is a continuous journey that requires ongoing attention and care.To talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.realhealthmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Welcome to my first solo AMA episode in quite some time!  I recently submitted the second round of edits for my book. That excited me and inspired me to reach out on social media and invite questions from my listeners and community. In my conversation today, I dive into weight loss resistance and reverse dieting, and I also share what I have been doing over the past year to build muscle.  Join me for a transparent and candid conversation, interwoven with questions from listeners and social media followers, where I answer many of the questions that matter most to you. IN THIS EPISODE, YOU WILL LEARN: Why the death of my father inspired me to back away from fasting and focus on strength training Changing my mindset to prioritize strength over thinness How the sex hormone shifts during perimenopause and menopause affect body composition The benefits of reverse dieting to improve metabolic health          Using strength training to counteract the effects of sarcopenia Chronic stress and its impact on cortisol levels and metabolic health inflammation levels and toxins from personal care products, food, and the environment Importance of prioritizing sleep  Connecting with hormone-savvy healthcare providers The best supplements for overall health Connect with Cynthia Thurlow   Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Books mentioned: Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives—Without Raising the Risk of Breast Cancer by Dr. Avrum Bluming and Dr. Carol Tavris The XX Brain: The Groundbreaking Science Empowering Women to Maximize Cognitive Health and Prevent Alzheimer's Disease by Lisa Mosconi

SEND US A TEXT MESSAGE!!! Let Drs. Nii & Renee know what you think about the show!We start off by discussing medical myths/traditions we should retire. We then talk about MTV personality Ananda Lewis, who died at age 52 from breast cancer after rejecting medical treatment in favor of detoxification.We dive deep into why patients have lost trust in healthcare providers and how the  medical credibility gap has widened dramatically in recent years. We conclude with Nii showing us his running equipment. FREE DOWNLOAD -  7 Considerations Before Starting Locum Tenens - https://darkos.lpages.co/7-considerations-before-locumsLINKS MENTIONED Q&A and Suggestions Form - https://forms.clickup.com/9010110533/f/8cgpr25-4614/PEBFZN5LA6FKEIXTWFSend us a Voice Message - https://www.speakpipe.com/docsoutsidetheboxSIGN UP FOR OUR NEWSLETTER! WATCH THIS EPISODE ON YOUTUBE!Have a question for the podcast?Text us at 833-230-2860Twitter: @drniidarkoInstagram: @docsoutsidetheboxEmail: team@drniidarko.comMerch: https://docs-outside-the-box.creator-spring.comThis episode is sponsored by Set For Life Insurance. What the Darkos use for great disability insurance at a low cost!! Check them out at www.setforlifeinsurance.com

If you've ever found yourself hurt, frustrated, or emotionally drained because someone didn't do what you thought they should—especially after you asked—this episode is for you. In this conversation, I'm talking about a powerful concept I use with my clients all the time, called “the manual.” It's the invisible rulebook we write in our minds about how other people should behave and what their actions (or lack of action) mean about us. But here's the catch: no one else has a copy of that manual. And when people don't follow our unspoken rules, we end up making it mean something painful—like “they don't care,” or “they don't love me.” That pain builds up, and it affects our emotional and physical health, especially when we're healing after something as life-changing as breast cancer. So in this episode, I'm sharing how to spot when you're living by a manual, how to burn it, and how to replace it with something far more powerful: clear, loving boundaries that support your peace and your healing.  

Physician Within Heal Thyself  Have you met your Physician- Within yet? Our Precognitive Dreams and Nightmares can deal with medical information, be Pearls of Wisdom, and be part of the ancient concept of “Physician Within Heal Thyself.” During this episode of Dreaming Healing, author and three-time Breast Cancer survivor Kat  Kanavos, aka The Queen of Dreams, discusses her Physician-Within, who introduces herself during a dream as Dr. Jules during an amazing Precognitive Diagnostic Dream. This is from Ch 25, pg 140 of her International multi award-winning book,  Surviving Cancerland: Intuitive Aspects of Healing.  BIO: Kathleen O'Keefe-Kanavos, aka Kat-The Queen of Dreams, is a three time breast cancer survivor, stage 4 recurrence, and Dream Expert who wrote the International and multi-award winning bestseller, Surviving Cancerland: Intuitive Aspects of Healing to help other people survive crisis. Her book is a path to wellness. She has shared her story on many platforms including Dr. Oz, the DOCTORS, and George Noory's, Coast to Coast AM , to name a few. Video Version: https://www.youtube.com/live/RsCvJOFO2sY?si=F4dTrEWMUXQpPiCg Chat with Kat during Live Show with Video Stream:  write a question on YouTube Have a Question for the Show? Go to Facebook– Dreams that Can Save Your Life Facebook Professional–Kathleen O'Keefe-Kanavos http://kathleenokeefekanavos.com/

Two things happened on the day I am recording this episode that make me think about how my life is different because of breast cancer.  I was doing so well not thinking about breast cancer today that I forgot to implement the usual precautions for avoiding any bug bites on my left arm. I was bitten by an ant on my left hand at the end of my walk today. Tiny ants biting seems like no big deal, but the general strategy for lymphedema prevention is to avoid impairing the integrity of the skin on the side where a lymph node dissection has been done. This includes avoiding bug bites! I know the risk of lymphedema developing in my left arm is actually very low, but I do not want to do anything that would potentially allow for breakdown in the skin on my left arm or hand.  As I was standing at the sink washing my hands after the ant incident, a flood of urine ran out of me. It left urine running down over my ankles, with visible streaks of urine on my pant legs and on the footbed of my sandals. I had no intention to sit on the toilet at this moment. What does this have to do with breast cancer life? Typically, with a pause I am able to get control of my bladder. Today was different. I cannot say for certain that I am having increased urinary urgency or incontinence because of my breast cancer treatment, but the symptoms are much worse than before I started tamoxifen in 2023. This urine flood reaffirms my recent decision to begin taking low-dose vaginal estrogen. I had discussed this option with my medical oncologist and my gynecologist last year. At the time I did not think I needed the estrogen, but after realizing the urinary side-effects I have are not getting better, I decided to get a prescription for vaginal estrogen. Without a cancer history, I would have not hesitated to add in estrogen as part of my peri-menopause or post-menopausal health care.  Breast cancer life changes everything! If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list! LET'S CONNECT: connect@breastcancerlife.org  Follow us on Pinterest   

Dr. Sujatha Kekada is the Head Physician and Co-Founder of AmrtaSiddhi Ayurvedic Clinic in Ubud, Bali. She is a certified Ayurvedic Doctor (B.A.M.S) with a degree from Rajiv Gandhi University, India. She talks with Colette about cancer with a particular focus on breast cancer and they discuss the following: Ayurveda's understanding of the root causes of breast cancer from an ama (toxins), dosha (vata, pitta and kapha), dhatu (tissue) and emotional perspective. The three ways cancer can manifest in the body. The importance of cleansing the body to prevent cancer and taking care of your breast tissue. Dr. Sujatha's approach to healing the body and mind. The role Ayurveda can play alongside allopathic treatment. Ayurveda's approach to recovery and healing after breast cancer treatment, including mastectomy or reconstruction. Preventive steps women take from an Ayurvedic perspective to maintain breast health. * Check out Dr. Sujatha's website here.... amrtasiddhi.com * Visit Colette's website www.elementshealingandwellbeing.com  Online consultations & Gift Vouchers Next discounted Group Cleanse starts October 3rd, 2025 Private at-home Digestive Reset Cleanse tailored to you Educational programs - Daily Habits for Holistic Health Have questions before you book? Book a FREE 15 min online Services Enquiry Call * Join the Elements of Ayurveda Community! * Check out the other episodes mentioned in this episode: 16 - Ayurvedic Dinacharya or Daily Routines 122 - Ayurvedic Ritucharya - Guidelines for the Seasons 244 - An Ayurvedic Digestive Reset Cleanse 263 - Ayurvedic View on the Menstrual Cycle 394 - Ayurvedic Wisdom on Exercise and Recovery Stay connected on the Elements Instagram and Facebook pages. * Enjoy discounts on your favourite Ayurvedic products: Banyan Botanicals - enter discount code ELEMENTSOFAYURVEDA at checkout for 15% off your first purchase.** Divya's  - enter discount code ELEMENTSOFAYURVEDA15 at checkout for 15% off your first purchase.** Kerala Ayurveda - enter discount code ELEMENTS15 to receive 15% off your first purchase.** LifeSpa - Save $10 on a $50 or more one-time purchase with the code elements10.  **Shipping available within the U.S. only. * Thanks for listening!  

Breast cancer is one of the most talked-about health issues in the world, but there's still so much we don't discuss. While mammograms and early detection campaigns have saved countless lives, the conversation often stops there.  What's missing is a deeper look at the lifestyle, genetic, and environmental factors that play a pivotal role in prevention, and the small, daily changes that can make a massive impact. Because here's the truth: 80% of breast cancer cases are not inherited. They're environmental. That means we have far more power than we think. But to tap into it, we need better guidance, smarter screening strategies, and a stronger understanding of how our bodies work. What kind of screenings should women get? How do factors like breast tissue increase the risk of breast cancer? In this episode, I'm joined by Dr. Pamela Smith, an internationally recognized functional medicine physician, author of 14 bestselling books, and co-director of the Personalized Medicine Certification at the University of South Florida.  She shares science-backed strategies to reduce your risk, strengthen your immune system, and support your body before and after a diagnosis. Things You'll Learn In This Episode  The 3 things that feed cancer Sugar, stress, and toxins are the trifecta that fuel cancer cell growth. But how do you realistically cut them out and what's secretly making them worse? Why 80% of breast cancer isn't genetic Family history matters but not as much as your environment. Which everyday exposures and habits have the biggest impact on your risk? The truth about hormones and alcohol Is hormone therapy safe? And what happens when you mix it with alcohol?  What most women don't know about screening Dense breast tissue, faulty methylation, even your gut health can affect your screening results. How do you make sure you're getting the full picture of your health?   Guest Bio Pamela Wartian Smith, M.D., MPH, MS is an internationally known speaker and author on the subject of Anti-Aging and Precision Medicine. She spent her first twenty years of practice as an emergency room physician with the Detroit Medical Center in a level 1 trauma center and then 28 years as an Anti-Aging/Functional Medicine specialist. She is a diplomat of the Board of the American Academy of Anti-Aging Physicians and is. Dr. Smith also holds a master's degree in public health and a master's degree in metabolic and nutritional medicine. She is in private practice and is the senior partner for The Center for Precision Medicine, with offices in Michigan and Florida. She has been featured on CNN, PBS, and many other television networks, has been interviewed in numerous consumer magazines, and has hosted two of her own radio shows. Dr. Smith was one of the featured physicians on the PBS series “The Embrace of Aging” as well as the online medical series “Awakening from Alzheimer's” and “Regain Your Brain”. She is the author of fourteen best-selling books, including How to Prevent Breast Cancer- Before & After: A Guide to Taking Back Control of Your Life. To learn more about Dr. Smith and to get her books, visit https://mdpamelasmith.com/.    About Your Host Hosted by Dr. Deepa Grandon, MD MBA, triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidenced-based lifestyle medicine.     ​​ Resources Feeling stuck and want guidance on how to transform your spiritual, mental and physical well being? Get access to Dr Deepa's 6 Pillars of Health video! Visit drdeepa-tlc.org to subscribe and watch the video for free. ‌ Work with Me Ready to explore a personalized wellness journey with Dr. Deepa? Visit drdeepa-tlc.org and click on “Work with Me” to schedule a free intake call. Together, we'll see if this exclusive program aligns with your needs!  Want to receive a devotional every week From Dr. Deepa? Devotionals are dedicated to providing you with a moment of reflection, inspiration, and spiritual growth each week, delivered right to your inbox. Visit https://www.drdeepa-tlc.org/devotional-opt-in to subscribe for free. Ready to deepen your understanding of trauma and kick start your healing journey? Explore a range of online and onsite courses designed to equip you with practical and affordable tools. From counselors, ministry leaders, and educators to couples, parents and individuals seeking help for themselves, there's a powerful course for everyone. Browse all the courses now to start your journey.   ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced. Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm so our show reaches more people. Thank you!

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

There are many acronyms, terms, and procedures patients hear either in consultation with their plastic surgeon or online through various social media groups and platforms. Our guest on this edition of the DiepCJourney podcast is a board-certified microsurgeon who will help us sort out three of those terms today. The delay procedure, SIEA, and TDAP in breast reconstruction surgery. We appreciate everyone who is utilizing the DiepCFoundation resources. Be sure to click here for the video interview with my guest at the DiepCFoundation YouTube channel. I am joined by Dr. James Craigie, who specializes and is trained in microsurgery. The primary focus at his practice at The Center for Natural Breast Reconstruction in Mt. Pleasant, SC, is performing complex breast reconstruction procedures which we will discuss in this interview. I want to highlight that Dr. Craigie works with a team of microsurgeons practicing the co-surgeon model in breast reconstruction surgery. To learn more about the benefits of the co-surgeon model check out a previous episode of the DiepCJourney podcast by clicking here. At the Foundation, our focus is to provide accurate information to our listeners and why I ask Dr. Craigie to join us to discuss specific procedures in this interview. The paper I reference in the interview on the value of the co-surgeon model in breast reconstruction can be found and read by clicking here. Connect with Dr. Craigie and his practice on the following platforms. Instagram: https://www.instagram.com/natural.breast.reconstruction/ Facebook: https://www.facebook.com/naturalbreastreconstruction LinkedIn: The Center for Natural Breast Reconstruction

TODAY ON THE ROBERT SCOTT BELL SHOW: RFK Defends Science, MAHA FDA Roadblock, Breast Cancer Rising, Endocrine Disruptors Impair Fertility, Ozempic as Cancer Cure?, Glycerinum, Following Orders vs Moral Compass, Arsenic Low Birthweight, Microbiome Clinical Care, Microplastic Brain, Mariachi's Replaced and MORE! https://robertscottbell.com/rfk-defends-science-maha-fda-roadblock-breast-cancer-rising-endocrine-disruptors-impair-fertility-ozempic-as-cancer-cure-glycerinum-following-orders-vs-moral-compass-arsenic-low-birthweight-m/ Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Host Melissa Berry sits down with Melissa Eppard, a triple negative breast cancer survivor and co-founder of Upstate Mary, a wellness brand focused on CBD-infused intimacy products. They talk about Melissa's personal breast cancer experience and the challenges many patients face with intimacy during and after treatment. Their conversation highlights the importance of addressing issues like vaginal dryness and the need for lubrication, which are often misunderstood, overlooked, and surrounded by shame. Melissa shares how CBD can help improve comfort and sexual wellness, while normalizing these conversations and taking the shame away. They also discuss the pressures both cancer survivors as well as their partners can feel around intimacy and the power of community support in reclaiming confidence and connection after cancer. This episode offers honest insights and encourages open conversations about sexual health for cancer survivors and their partners.

Has cancer ever made you feel like you're losing a piece of yourself, especially your identity? Imagine facing hair loss from treatment, only to find the wig options available don't reflect who you are. This isn't just about hair; it's about dignity, self-esteem, and seeing yourself truly represented.In this powerful rebroadcast, join your host, Talaya Dendy, on Navigating Cancer TOGETHER as she welcomes the incredible Dianne Austin. A breast cancer survivor herself, Dianne co-founded Coils to Locs, a groundbreaking initiative born out of a deeply personal struggle. Prepare to be inspired by her journey to transform the wig industry and support women of color facing hair loss due to cancer and other medical conditions.

Camidge and O'Riordan discussed how O'Riordan's breast surgery career intersected with her personal experience with breast cancer. She shared the stories behind her initial diagnosis, subsequent treatments, and disease recurrences. She also emphasized the importance of open communication with patients about aspects of cancer survivorship, such as emotional wellbeing and sexual health. O'Riordan also talked about her career transition from the surgery field to patient advocacy, as well as her future plans for writing, speaking, and offering support to the breast cancer community. 

In this episode of the ACRO podcast CURiE edition, CURiE Channel Editor Dr. Jessica Schuster speaks with author Dr. Shearwood McClelland, III about his published article, "Early Implementation of the Navigator-Assisted Hypofractionation (NAVAH) Program in Hispanic-American Breast Cancer Patients." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science.Read the article here: https://www.cureus.com/articles/363179-early-implementation-of-the-navigator-assisted-hypofractionation-navah-program-in-hispanic-american-breast-cancer-patients#!/

When a loved one is diagnosed with breast cancer, the journey touches every corner of life —especially for caregivers. In honor of Black Family Cancer Awareness Week, for this powerful episode of Real Pink, we sit down with two incredible Black men of faith, Kenneth White, spiritual adviser and group facilitator for a national addiction treatment center, and John K. Conner of Praise Is the Cure, a nonprofit focused on breast cancer awareness in the Black community, as they open up about supporting their wives through breast cancer. Through a lens of faith and cultural identity, Kenneth and John reflect on what it means to show up with strength and vulnerability, how spirituality grounds their caregiving and the importance of community for Black families facing a diagnosis. Their stories illuminate a side of breast cancer that's often unheard — but deeply needed.

Red Lights, Green Lights – Understanding Breast Cancer RiskIn today's episode, Dr. Barbara 'Menopause' Taylor uses a simple analogy to explain the progression and prevention of breast cancer. She explores how various genetic, hormonal, and lifestyle factors act as either red lights (stopping cancer) or green lights (allowing it to develop). With clarity and compassion, she empowers you to become your own “traffic cop” in managing risk and making informed decisions about your health during menopause.Visual learner? Find the corresponding Menopause Taylor YouTube video here. Click here for more about one-on-one consultations and Dr. Taylor's menopause resources. Looking for a roadmap to successful menopause management? Dr. Taylor's new ebook, How to Win at Menopause: A Guide to Raising - and Winning- Your Game Your Way, will bring confidence and clarity to your menopause journey. Avoid common pitfalls and learn to navigate a healthcare system that focuses more on disease than prevention, where many professionals lack the relevant education and/or the motivation to help you.

Welcome to another powerful episode of The Power of Owning Your Career podcast! Have you ever wondered what it truly takes to pivot from a successful corporate path to building your own empire, all while navigating life's biggest challenges? This week, host Simone E. Morris interviews the phenomenal Dr. Cree Scott—founder and CEO of Serenity Psy Consulting, an executive coach, and a consulting psychologist with over 15 years of experience. Dr. Scott brings a wealth of knowledge in human-centered leadership development, change management, and cultivating employee well-being.   Dr. Scott shares her remarkable and often winding journey to entrepreneurship in this incredibly inspiring conversation. You'll hear about the pivotal moments that led her to bravely leave a thriving corporate role, how her courageous battle with breast cancer profoundly reshaped her approach to career ownership and well-being, and the wisdom she gained every step of the way.   Simone and Dr. Scott dive deep into critical strategies for aligning your professional life with your deepest personal values, the essential role of experimentation and faith when taking bold career risks, and the immense power of staying curious and connected throughout your professional evolution. Dr. Scott also opens up about the invaluable lessons gleaned from her diverse experiences—from thriving as a consultant at major firms to her lifelong pursuit of learning and growth.   Whether you're actively contemplating a significant career pivot, searching for tangible ways to take charge of your professional path, or simply looking for the ultimate inspiration to bet on yourself, this episode is an absolute must-listen. It's packed with practical insights, heartfelt stories, and the motivation you need to confidently get—and stay—in the driver's seat of your own career.   Don't miss a single moment of this transformative conversation! Tune in now and start owning your career today.   Episode Time Stamp: 00:00 Career Reflection: Lost in Advancement 03:43 Reevaluating Life and Career Choices 07:15 Finding Spirituality After Cancer 12:57 "Charting My Leadership Path" 14:35 "Embracing Adventure with Purpose" 17:37 Impact of Doctorate Degree 20:55 Betting on Faith and Self 24:06 Embracing Life's Uncertainty 27:00 "Connector of Diverse Identities"   ✴️ Resources: Book Recommendations: Reinventing You by Dorie Clark The Untethered Soul by Michael Singer The Seat of the Soul by Gary Zukav Books by Wayne Dyer Audible (as a resource for listening to books) Virtual connections and networking conversations Serenity Psy Health website (www.serenity.psyhealth.com) LinkedIn for professional networking   ✴️ Connect with our guest, Dr. Cree Scott: Dr. Cree Scott recommends reaching out to her on LinkedIn—search for "Cree Scott" (with or without the "Dr." in front). She personally manages her social media and welcomes direct messages if you want to connect or have a conversation. You can also visit her website at www.serenity.psyhealth.com for more information.   ✴️ Connect with the show's host, Simone E. Morris: https://www.linkedin.com/in/simonemorris/   ✴️ Want to apply to be a guest or recommend someone for the show?   Visit: https://bit.ly/pooycshowguest   ✴️ Get More Support for Your Career:

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.

Is weight gain one of your post-treatment challenges? While treatment can be both a direct and indirect cause of weight gain, your weight may be up for reasons you've not even considered! Tune in to this episode to find out what they are as I highlight and explain hidden reasons behind your tighter jeans and a higher number on the scale._____________________________________Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here!Follow me on Instagram @hormone.breastcancer.dietitian

In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsburgh, with 30 years of experience, whose expertise has helped shape the direction of treatment. Trials discussed include the SERENA-6 trial, which examines camizestrant plus CDK4/6 inhibitors in HR-positive, ESR1 mutation breast cancer; the DESTINY-Breast09 trial, highlighting trastuzumab deruxtecan in combination with pertuzumab; and the INAVO120 trial, revealing inavolisib's triplet therapy response in PIK3CA-mutated, HR-positive, HER2-negative disease. Join us for a deep dive into these game-changing findings and their impact on patient care.Studies discussed in the episode:SERENA-6DESTINY BREAST 09INAVO 120For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

"In my mind, I'm not going anywhere anytime soon." It's been a whirlwind week. THANK YOU for all of the love, support, and kindness after last week's "we're due for a catch-up" episode. It's been an overwhelming time for me — but what about for my support squad? I get so many questions from people asking how best to show up for someone going through a hard time, and my team and I have learned a lot about what this can all look like. So for this one, Cousin Jackie returns, and we're talking about what the past few weeks have been like for each of us: the patient and the support person. SPONSORS:  Oofos: The best in recovery footwear! Check out Oofos's 2025 Project Pink collection, where 10% of every purchase is donated to cancer research.  Vuori: Click here for 20% off your first Vuori purchase. Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

In this episode of The Breast Cancer Recovery Coach, we'll dismantle three of the most common—and misleading—nutrition myths that many women encounter after a breast cancer diagnosis. Whether you're in active treatment or navigating life post-cancer, this conversation offers clarity, compassion, and practical advice rooted in science, not fear.   You'll learn: Why not all carbohydrates are harmful and how whole-food carbs can actually support healing The truth about plant vs. animal foods and how to identify clean, high-quality animal proteins How “organic” and “plant-based” labels can mislead your food choices—and what to look for instead If you've ever felt confused or overwhelmed by nutrition advice, this episode will help you reconnect with your body, make informed choices, and feel confident in the way you nourish yourself. Topics Covered: The real difference between simple and complex carbohydrates How to eat carbs while maintaining stable blood sugar Nutrient density and bioavailability of animal vs. plant foods What qualifies as a clean animal food and why it matters The “health halo effect” of organic and plant-based labels Tips for tuning out food fear and tuning into what works for your body   Resources & References: Work with Laura Study: Glycemic load and cancer risk – Nutrition Journal Study: Dietary fiber intake and breast cancer – Annals of Oncology Study: Macronutrient combinations and glycemic response – Diabetes Care Study: Organic labeling and perception – Food Quality and Preference Study: Health halo of plant-based labels – Appetite (2018) Study: Plant-based health halo and risk perception – Appetite (2019)   Loved this episode? Share it with a friend or leave a review on Apple Podcasts to help more survivors find compassionate, clear guidance on living well after breast cancer.   Connect with Laura Lummer:

 NEW EPISODE | The Doctor Who Couldn't Zip Her Dress: A Breast Cancer StoryThis week on The Brain Love Podcast, Dr. Delvena Thomas sits down with a courageous family practice physician, Dr. Michelle Powell, who became the patient.  Diagnosed with breast cancer during the pandemic, she opens up about the emotional rollercoaster of treatment—from the strength it took to keep practicing medicine, to the day chemo made her too weak to zip her own dress.As a psychiatrist, Dr. Thomas was deeply moved by her vulnerability, her resilience, and the raw honesty she brings to this conversation. This isn't just a story about survival—it's a story about identity, womanhood, and healing. “I couldn't even zip my dress… and I'm a doctor. I help people heal—but I couldn't help myself.” Tune in for a powerful blend of medical insight and human connection. We are in season 6, epi #2!#BrainLovePodcast #BreastCancerAwareness #SurvivorStory #PhysiciansArePatientsToo #MentalHealthMatters #HealingJourney #WomenInMedicine #Resilience #ChemoChronicles #BlackDoctorsMatter #UnzipTheStigma#BrainLove

Heartfelt tributes pour in for former MTV and BET host Ananda Lewis, who passed away at 52 after a seven-year battle with breast cancer. Known for her authenticity, advocacy, and shining presence on Teen Summit and Total Request Live, Ananda used her platform to encourage early cancer screening and embrace tough health conversations. See omnystudio.com/listener for privacy information.

In this week’s The Rickey Smiley Morning Show Podcast, heartfelt tributes pour in for former MTV and BET host Ananda Lewis, who passed away at 52 after a seven-year battle with breast cancer. Known for her authenticity, advocacy, and shining presence on Teen Summit and Total Request Live, Ananda used her platform to encourage early cancer screening and embrace tough health conversations. The show also covers Simon Guobadia’s deportation back to Nigeria by ICE—a move that complicates his divorce from RHOA star Porsha Williams and stirred debate about immigration enforcement and celebrity courts. Tyrese Gibson joins the crew in studio to promote his involvement on the Tom Joyner cruise and share his unfiltered thoughts on staying relevant and releasing new music. Finally, Nicki Minaj drops her latest hot-take alongside Lil Wayne in the “Banned from NO” remix—laying into the NFL for overlooking Lil Wayne during the Super Bowl halftime, reigniting conversations around hip-hop’s role in sports entertainment. Website: https://www.urban1podcasts.com/rickey-smiley-morning-show See omnystudio.com/listener for privacy information.

Today's guest is discussing genetic testing, specifically because she has tested positive for a strong breast cancer gene. She believes this is the same gene that caused her mother to have breast cancer. I've often wondered, if a close relative has had cancer, does that increase my chances of developing it as well? What steps can be taken to prevent cancer if there is a significant family history of it? How "close" does a relative need to be for their cancer diagnosis to raise their own risk? Krista answered all these questions and so many more. This is a tricky topic, and I'll be honest, it's a little scary when you think about getting tested to see if you have a higher likelihood of cancer. However, Krista is very clear that knowledge is power, and it's better to understand the risks associated with your genetics so you can take action to mitigate them. A couple of our takeaways: We had an enlightening conversation about the relationship between stress and cancer. We both know that stress plays a huge role in cancer. We both agree that organic produce is the best choice, though we recognize that it can be expensive. We discussed some creative strategies for incorporating 8 to 10 servings of organic produce into our daily diets without overspending. ______ Bon Charge Do you want to know one of my wellness secrets?  I'm a huge fan of red light therapy—it's been a powerful tool throughout my health journey. I've personally experienced its benefits in reducing inflammation, speeding up wound healing, and supporting muscle recovery.  Click here to see my favorite brand. ______ Just Add Buoy What to see what I'm drinking?! I've been looking for an electrolyte product for YEARS. This is why I'm so happy to have found BUOY Electrolyte drops. Click here to get 20% off my drink of the summer! ______ Connect with Krista Instagram: https://www.instagram.com/cancer.prevention.coach/?hl=en ______ Connect with Deborah Deborah on Instagram: https://www.instagram.com/whydidigetcancer/ Deborah on Facebook: https://www.facebook.com/DebsHealthCoachKitchen Deborah on Twitter: https://twitter.com/ydidigetcancer Deborah on Pinterest: https://in.pinterest.com/whydidigetcancer/ Join Deb's weekly newsletter!  -https://whydidigetcancer.us14.list-manage.com/subscribe?u=1c37affeccf004c8957941069&id=a8572db3c2

Please note: This episode has been updated to reflect a minor edit made after the initial relase.   On this episode of the Natasha Helfer Podcast, one of Natasha's providers, Sara Rands, ACMHC, joins to discuss her journey with a chronic illness and how that affects intimacy. She's Master Certified in Accelerated Resolution Therapy (ART), a brain-based therapy that clears stuck emotional patterns without the need to relive painful stories. Her approach blends structure and soul: existential therapy, mindfulness, ketamine-assisted psychotherapy (KAP), and current training in the NARM model for complex trauma. Sara works especially well with gifted, neurodiverse, and highly sensitive clients—analytical minds, deep thinkers, and those who've always moved through life a little differently. She brings lived wisdom from cancer survivorship, spiritual transitions, and parenting spectrum kids. With a background in both computer science and English, she offers a calm, curious, and focused presence and a rare ability to hold emotional complexity without simplifying it. Go here for more on Sara: https://symcounseling.com/sara-rands/   To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com.  The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.

In this episode I'm going to help you answer the question: should I be starting hormone replacement therapy during peri or post menopause? Over the past 23 years, there has been a lot of fear about hormone replacement therapy (HRT). The Women's Health Initiative originally reported a concern about breast cancer risk, and that led many women to avoid hormone replacement. A newly updated report from the same researchers has completely changed the perspective on hormone replacement. The researchers are now stating that HRT is not increasing breast cancer risk the way they once feared. Instead, HRT can actually decrease disease risk, including by decreasing heart disease, dementia, diabetes, and osteoporosis. That is such essential information, and such a shift in what we've been hearing, that I wanted to cover this topic in detail. Choosing hormone replacement therapy is a very individualized decision. It's important to understand and think through your medical history and your health risk factors. It's also important to work with a practitioner who understands the latest research. It is essential to individualize your doses and how hormones are delivered to your body (oral, cream, patch, etc). I'm going to cover how to find a practitioner who can guide you every step of the way. I'm here to help you! LINKS FROM THE EPISODE:   Take Dr. Doni's Stress Type Quiz: https://doctordoni.com/quiz/stress-quiz/   Menopause Program with Dr. Doni: https://dv296.infusionsoft.com/app/orderForms/Menopause    Sign up For Dr. Doni's Masterclasses: https://doctordoni.com/masterclasses/    Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

In this episode, we continue with a special series close to my heart: Decoding Destiny: Navigating Breast Cancer with Genetic Insight. I'm joined by Kathy Baker, patient advocate and founder of My Faulty Gene to explore the power of genetic testing—particularly cascade testing—and how it can help both you and your family take control of your breast cancer risk. Kathy shares her compelling personal story and how it inspired her to launch My Faulty Gene, a nonprofit organization that provides education, emotional support, and financial assistance for genetic testing. You'll learn all about the importance of cascade testing for families, how genetic knowledge can lead to proactive screenings and preventive health measures, and how advocacy is truly paving the way for more accessible care. Whether you're facing a BRCA-positive diagnosis, considering genetic testing, or looking for support navigating hereditary cancer risk, this is one conversation that you'll want to listen to - and share with your entire family.  Thank you to Merck and AstraZeneca for making this episode possible!

In today's episode, we spoke with Paolo Tarantino, MD, about key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

What did you think of this episode?Finding the right endorsers for your book is possible!If you have endorsers, are they the right fit for your book? Today's encore episode shares six essential tips for finding and leveraging the best endorsements for your book. Welcome to Your Best Writing Life, an extension of the Blue Ridge Mountains Christian Writers Conference held in the beautiful Blue Ridge Mountains of North Carolina. I'm your host, Linda Goldfarb. Each week, I bring tips and strategies from experts in the writing and publishing industry to help you excel in your craft. I'm so glad you're listening in; during this highly praised encore episode, you'll learn the … Top Six Tips to Find and Use Book Endorsements.My industry expert is… Ginny Brant. Ginny is a speaker and writer who grew up in our nation's capital. Her award-winning book, Finding True Freedom, was endorsed by Chuck Colson. Her recent book, Unleash Your God-given Healing, has won five awards. Both books received media interviews nationwide. Ginny has also written over 200 articles. Ginny shares her Top Three Tips to Locate Endorsersand her Top Three Tips to Leverage Endorsements :Endorsers can be used to validate and market a book. Choose endorsers who bring different perspectives to your book's message. Be intentional in who you choose to write the forward. LINKSListener giveaway - Free tips for Reducing Risk for Breast Cancer  www.ginnybrant.com/unleashUnleash Your God-Given Healing: Eight Steps to Prevent and Survive Cancerhttps://www.amazon.com/Unleash-Your-God-Given-Healing-Prevent/dp/1973688123/      Finding True Freedom, From the White House to the World https://www.amazon.com/Finding-Freedom-White-House-World/dp/1936143097 You can find out more about Ginny Brant www.ginnybrant.com https://www.facebook.com/ginny.d.brant/  https://www.instagram.com/ginnydentbrant/     https://www.linkedin.com/in/ginny-brant-aa5153a/ Ginny Brant's Books:https://www.amazon.com/Unleash-Your-God-Given-Healing-Prevent/dp/1973688123/https://www.amazon.com/Finding-Freedom-White-House-World/dp/1936143097 Visit Your Best Writing Life website.Join our Facebook group, Your Best Writing LifeYour host - Linda Goldfarb#1 Podcast in the "Top 50+ Must-Have Tools and Resources for Christian Writers in 2024". Awarded the Spark Media 2022 Most Binge-Worthy PodcastAwarded the Spark Media 2023 Fan Favorites Best Solo Podcast

Ep 69: In this episode of Strength To Build, Chelsey sits down with actress, breast cancer survivor, and recent college grad - Miranda McKeon for an honest conversation about how her approach to health, fitness, and mental resilience helped her navigate breast cancer—diagnosed at just 19 years old.Miranda shares what her relationship with health looked like before her diagnosis, how she adapted her routine during treatment, and how she continues to rebuild both physically and emotionally after surviving cancer.This conversation is a reminder that fitness isn't just about aesthetics—it's a tool for strength, healing, and self-confidence. Miranda's story is vulnerable, powerful, and filled with insight for anyone navigating a health challenge or supporting someone who is.Follow Miranda on Instagram: @mirandamckeonStart your 7 day FREE trial of my new app HERE!Want to work one on one with Chelsey?Set up a one on one consultation call here to see if personalized online training is right for you.Join a semi-private class in LA here.Email info@chelseyrosehealth.com to inquire about one on one in person training.Follow Chelsey on Instagram:@Chelseyrosehealth@StrengthtobuildFollow Chelsey on TikTok Here."Submit a question to the show"

What do you do when cancer is always present in your family? David Mauk lost his mother, his sister, and other loved ones to breast cancer. He knows what it's like to grow up surrounded by the reality of cancer and to carry the BRCA gene. In today’s episode, you’ll hear: How genetic testing changed the choices his family made What it feels like to be a cancer advocate in Washington, D.C. Why sharing your family history can help save lives Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What impact did breast cancer have on David Mauk's family? What is the significance of the BRCA gene in David’s family? How did David’s family talk about breast cancer while he was growing up? How did David cope with losing his mother at such a young age? Did David himself undergo genetic testing and what were the results? How does David’s family approach genetic testing and health surveillance today? What has David done as an advocate for cancer research and awareness? Why does David believe early detection and knowing your family history is so crucial? What advice does David have for those with a family history of cancer? How has cancer research and treatment changed since previous generations? Timestamped Overview 00:00 Family, Cancer, Advocacy, Gene Awareness 04:31 Air Force Headsets Linked to Tumors 07:36 "Air Force Brat’s Journey" 11:07 Cancer Society Fundraising Champions 14:11 "Make Cancer Conversations Personal" 15:41 "Missing Maternal Memories" 22:00 Family Migration Journey 22:57 Living Positively Amidst Fear 25:57 Discovering Family Through DNA Insights 29:37 Empowering Young Women Against Breast CancerSee omnystudio.com/listener for privacy information.

Headlines: – Welcome to Mo News (02:00) – Trump Deploys National Guard To LA After Violence Anti-Ice Protests (05:40)– CA Governor Suing Administration Over Move (16:25)– Analysis On Why Trump Escalating Raids (17:40) – Abrego Garcia Is Back In The U.S. To Face Charges (24:15) – President Trump's Travel Ban Goes Into Effect Today (30:10) – Elon Musk's Behavior Behind Trump's Fallout With Ex-DOGE Head (33:10) – New Era in College Sports: Schools Cleared to Pay Student Athletes (37:40) – Younger Women See Alarming Rise in Breast Cancer Diagnoses (40:50) – French Open Champion's First Stop Revelation About Parents (44:00) – On This Day In History (47:20) Thanks To Our Sponsors: – LMNT - Free Sample Pack with any LMNT drink mix purchase – Industrious - Coworking office. 30% off day pass – Athletic Greens – AG1 Powder + 1 year of free Vitamin D & 5 free travel packs – Shopify – $1 per-month trial Code: monews – Incogni - 60% off an annual plan| Promo Code: MONEWS – Saily - 15% off any data plan | Promo Code: MONEWS

Need Prayer? Send Us a DM @chosenbyjesuscbj How do you anchor your faith when trauma tries to return-before you even know the outcome? In this powerful episode of Chosen by Jesus, Kelley Tyan and her daughter Taylor Tyan open up about discovering a new mass-more than a decade after surviving breast cancer. The fear came rushing back, but her response was different.  You'll learn how to: *Anchor your faith when anxiety resurfaces *Speak truth when emotions try to take over *Choose peace in the unknown *Trust God's presence more than your fear "We have this hope as an anchor for the soul, firm and secure." Hebrews 6:19 This one's for anyone walking through fear, illness, trauma, or spiritual storms. You're not alone. God is with you. CONNECT WITH KELLEY AND TAYLOR: Watch the show on YouTube ChosenbyJesus-CBJ Follow Kelley & Taylor on Instagram @chosenbyjesuscbj Visit Kelley's website: www.kelleytyan.com Grab Kelley's free 5 day devotional 

If your doctor is recommending that you get a mastectomy, you will likely have some choices about how the surgery is performed. Your breast cancer treatment, your body, your breast shape and your lifestyle affect not only your options, but also the pros and cons of your options. There's no one method that works best for everyone because each person is unique. Today we are going to be exploring one specific type of mastectomy – the nipple-sparing mastectomy. This is a skin-sparing mastectomy that leaves the nipple and areola intact and usually improves the overall look of the reconstructed breast. Joining us on the show today are two very special guests: Dr. Mara Piltin, a Breast and Melanoma Surgical Oncologist and Physician Assistant, Maddie Beiswanger, both from Mayo Clinic. They are going to tell us more about nipple-sparing mastectomy procedures, current research that is being conducted around the use of minimally invasive robotic surgery to assist in these procedures and the possible benefits that these innovations can provide. This episode of The Real Pink Podcast is brought to you by Intuitive Surgical. Intuitive is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Intuitive has been advancing minimally invasive care since 1995 with the goal of helping physicians improve the lives of people around the world. You can learn more at www.Intuitive.com

The Pathology of Breast Cancer (YouTube Video #386)In this episode, Dr. Barbara 'Menopause' Taylor demystifies the process of how normal breast cells become cancerous. Using clear analogies and a step-by-step breakdown, she walks you through the stages from healthy tissue to invasive cancer—showing how breast cancer develops slowly over time. Learn about different breast cancer types, the meaning behind terms like “hyperplasia” and “carcinoma in situ,” and why understanding pathology can bring you peace of mind.Visual learner? Find the corresponding Menopause Taylor YouTube video here. Click here for more about one-on-one consultations and Dr. Taylor's menopause resources. Looking for a roadmap to successful menopause management? Dr. Taylor's new ebook, How to Win at Menopause: A Guide to Raising - and Winning- Your Game Your Way, will bring confidence and clarity to your menopause journey. Avoid common pitfalls and learn to navigate a healthcare system that focuses more on disease than prevention, where many professionals lack the relevant education and/or the motivation to help you.

“This sucks, and it's going to be hard, and this is very real. But that doesn't mean we're going to stop having fun along the way. So let's have fun when it feels right.” We're due for a catch-up. SPONSOR:  UCAN: Click here to get a FREE UCAN sample pack (you'll just pay the cost of shipping), and use code ALI for 20% off your entire UCAN order. Follow: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT: If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. And if you liked this episode, share it with your friends!